Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,880 | 1 | 55.1% |
| Travel and Lodging | $1,726 | 3 | 33.0% |
| Food and Beverage | $479.53 | 6 | 9.2% |
| Education | $143.97 | 3 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,708 | 7 | $0 (2024) |
| Astellas Pharma US Inc | $238.52 | 4 | $0 (2020) |
| Genentech USA, Inc. | $173.48 | 1 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $109.58 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,708 | 7 | E.R. Squibb & Sons, L.L.C. ($4,708) |
| 2022 | $173.48 | 1 | Genentech USA, Inc. ($173.48) |
| 2020 | $29.99 | 1 | Astellas Pharma US Inc ($29.99) |
| 2018 | $28.99 | 1 | Astellas Pharma US Inc ($28.99) |
| 2017 | $289.12 | 3 | Astellas Pharma US Inc ($179.54) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,880.00 | General |
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $1,023.48 | General |
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $254.80 | General |
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $50.80 | General |
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $35.79 | General |
| 06/28/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.33 | General |
| 06/27/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $448.05 | General |
| 05/13/2022 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $173.48 | General |
| Category: BioOncology | ||||||
| 01/29/2020 | Astellas Pharma US Inc | — | Education | In-kind items and services | $29.99 | General |
| 06/22/2018 | Astellas Pharma US Inc | — | Education | In-kind items and services | $28.99 | General |
| 11/28/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $84.99 | General |
| 05/17/2017 | Merck Sharp & Dohme Corporation | DIFICID (Drug) | Food and Beverage | In-kind items and services | $109.58 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/11/2017 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $94.55 | General |
| Category: Infectious Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 151 | 352 | $116,781 | $32,052 |
| 2022 | 5 | 165 | 420 | $127,328 | $35,990 |
| 2021 | 5 | 169 | 410 | $122,273 | $35,068 |
| 2020 | 6 | 191 | 473 | $126,500 | $32,116 |
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 46 | 144 | $54,664 | $16,265 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 56 | 146 | $45,089 | $11,138 | 24.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $5,391 | $1,744 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 24 | 33 | $8,981 | $1,659 | 18.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 13 | 17 | $2,656 | $1,245 | 46.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 54 | 228 | $69,084 | $17,994 | 26.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 48 | 112 | $41,776 | $13,194 | 31.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 32 | 44 | $11,440 | $2,322 | 20.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 15 | 20 | $3,060 | $1,644 | 53.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 16 | 16 | $1,968 | $836.09 | 42.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 52 | 221 | $66,963 | $17,975 | 26.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 46 | 94 | $35,062 | $11,486 | 32.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 41 | 59 | $15,340 | $3,195 | 20.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 12 | 16 | $2,448 | $1,346 | 55.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 18 | 20 | $2,460 | $1,067 | 43.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 67 | 291 | $78,111 | $18,421 | 23.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 39 | 82 | $28,538 | $7,517 | 26.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 25 | 32 | $4,896 | $2,121 | 43.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $4,929 | $1,832 | 37.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 22 | 28 | $3,444 | $1,185 | 34.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 25 | 27 | $6,582 | $1,039 | 15.8% |
About Dr. Humera Khurshid, MD
Dr. Humera Khurshid, MD is a Hematology & Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1013991926.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Humera Khurshid, MD has received a total of $5,230 in payments from pharmaceutical and medical device companies, with $4,708 received in 2024. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($2,880).
As a Medicare-enrolled provider, Khurshid has provided services to 676 Medicare beneficiaries, totaling 1,655 services with total Medicare billing of $135,225. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Providence, RI
- Active Since 12/05/2005
- Last Updated 08/17/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013991926
Products in Payments
- TECENTRIQ (Biological) $173.48
- DIFICID (Drug) $109.58
- Cresemba (Drug) $94.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Providence
Ritesh Rathore, Md, MD
Hematology & Oncology — Payments: $324,296
Anthony Mega, Md, MD
Hematology & Oncology — Payments: $193,307
Dr. Adam Olszewski, M.d, M.D
Hematology & Oncology — Payments: $47,507
John Reagan, Md, MD
Hematology & Oncology — Payments: $35,520
Hina Khan, M.d, M.D
Hematology & Oncology — Payments: $19,225
Dr. Joseph Dibenedetto, Md, MD
Hematology & Oncology — Payments: $6,205